Evoke Pharma announces USPTO issuance of new GIMOTI patent expiring Nov 2038

Evoke Pharma Inc

U.S. Patent No. 12,377,064 covers intranasal metoclopramide for moderate to severe gastroparesis.
Patent term adjusted to November 2038 by the USPTO.
Company plans to list the new patent in the FDA Orange Book.

item 8.01

Source: SEC EDGAR

accession 0000950170-25-103504

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.